We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies. Close

Watson and Takeda resolve Actos litigation

Patent World Magazine

Watson and Takeda resolve Actos litigation

UNITED STATES – US generic drugs company Watson Pharmaceuticals has settled its patent litigation with the Japanese firm Takeda Pharmaceuticals over, Takeda’s diabetes drug Actos (pioglitazone). Under the terms of the agreement, Takeda has granted Watson a non-exclusive, royalty-free licence to its patents covering pioglitazone. Watson will be able to launch a generic version of the drug in August 2012. The patents covering the drug expire in 2016, according to the Food and Drug Administration.

The rest of this document is only available to i-law.com online subscribers.

If you are already a subscriber, please enter your details below to log in.

Enter your email address to log in as a user on your corporate account.
Remember me on this computer

Not yet an i-law subscriber?

Devices

Request a trial Find out more